Physician profile
Robert Seltzer
NPI 1437127099
$7,150.59
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,631 · 2020: $1,464 · 2021: $1,658 · 2022: $1,398.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $916.00 | 2019-2022 | |
| Leo Pharma INC. | $744.02 | 2019-2022 | |
| Abbvie INC. | $634.91 | 2019-2022 | |
| Genzyme Corporation | $575.59 | 2019-2022 | |
| Janssen Biotech, INC. | $518.40 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $513.09 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $412.53 | 2019-2022 | |
| Allergan, INC. | $404.51 | 2019 | |
| Pfizer INC. | $327.79 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $278.86 | 2020-2022 | |
| Epi Health, LLC | $275.13 | 2019-2022 | |
| Almirall LLC | $256.32 | 2019-2022 | |
| Amgen INC. | $235.39 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $212.62 | 2019-2020 | |
| Journey Medical Corporation | $200.57 | 2020-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $129.71 | 2019-2022 | |
| Dermira, INC. | $114.33 | 2019-2021 | |
| Prugen, INC. Pharmaceuticals | $86.57 | 2019 | |
| Incyte Corporation | $59.66 | 2022 | |
| Celgene Corporation | $47.41 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $42.35 | 2019 | |
| Dusa Pharmaceuticals, INC. | $40.21 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.70 | 2019-2020 | |
| Ucb, INC. | $37.20 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.43 | 2022 | |
| Merck Sharp & Dohme LLC | $18.29 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Seltzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.